|
|
|
|
| LEADER |
01557nam a2200277 u 4500 |
| 001 |
EB002136261 |
| 003 |
EBX01000000000000001274388 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
221206 r ||| eng |
| 100 |
1 |
|
|a Khangura, Sara
|
| 245 |
0 |
0 |
|a Premium versus standard intraocular lenses for cataracts
|h Elektronische Ressource
|b a review of clinical effectiveness and cost-effectiveness
|c authors, Sara D. Khangura, Lorna Adcock, Kaitryn Campbell
|
| 250 |
|
|
|a Version: 1.0
|
| 260 |
|
|
|a [Ottawa]
|b Canadian Agency for Drugs and Technologies in Health
|c 2018, June 18, 2018
|
| 300 |
|
|
|a 1 PDF file (42 pages)
|b illustration
|
| 700 |
1 |
|
|a Adcock, Lorna
|e [author]
|
| 700 |
1 |
|
|a Campbell, Kaitryn
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK581858
|3 Volltext
|
| 082 |
0 |
|
|a 580
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a Because of the potential benefits that premium intraocular lenses (IOLs) may offer, alongside the potential for increased expense on the part of the patient and/or third-party payers, evidence is needed to inform decision-making. This report aims to synthesize available evidence on the comparative clinical effectiveness and cost-effectiveness of premium compared with standard monofocal IOLs for patients with cataracts
|